QGEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Qiagen NV (QGEN) is not a strong buy for a beginner, long-term investor at this time. While the company has shown positive financial growth in the latest quarter and has a stable portfolio, the lack of significant positive catalysts, hedge fund selling, and mixed analyst sentiment suggest waiting for a clearer entry point. The technical indicators and options data do not strongly support an immediate buy decision.
The MACD is positive at 0.43, indicating bullish momentum, but it is contracting. The RSI is neutral at 46.929, showing no clear overbought or oversold condition. Moving averages are converging, suggesting indecision in price trends. Key support is at 39.994, and resistance is at 42.065, with the current pre-market price of 41.465 near the pivot level of 41.029.
The company's financials for Q4 2025 showed revenue growth of 3.69% YoY, net income growth of 22.09% YoY, and EPS growth of 28.95% YoY. The company has a robust balance sheet and attractive growth drivers like Quantiferon and Qiastat.
Options data shows a low Put-Call Ratio, indicating limited bullish sentiment.
In Q4 2025, Qiagen reported revenue of $540.42M (up 3.69% YoY), net income of $107.83M (up 22.09% YoY), and EPS of $0.49 (up 28.95% YoY). However, gross margin declined to 59.83% (down -6.85% YoY).
Analyst sentiment is mixed. Recent downgrades include Barclays lowering its rating to Equal Weight from Overweight with a reduced price target of $44. However, Deutsche Bank upgraded the stock to Buy, citing an undemanding valuation and robust balance sheet. Price targets range from $44 to $60, with a median target of approximately $52.
